Influence of severity of anemia on clinical findings in infants with sickle cell anemia: Analyses from the BABY HUG study

Pediatric Blood and Cancer

Volumn 59, Issue 4, 2012, Pages 675-678

  Lebensburger, Jeffrey D ^a   Miller, Scott T ^b   Howard, Thomas H ^a   Casella, James F ^c   Brown, R Clark ^d   Lu, Ming ^e   Iyer, Rathi V ^f   Sarnaik, Sharada ^g   Rogers, Zora R ^h   Wang, Winfred C ⁱ  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d EMORY UNIVERSITY   (United States)

^e Clinical Trials & Surveys Corp   (United States)

^f UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^g CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

ⁱ ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Acute chest syndrome; Hydroxyurea; Pain; Renal; Sickle cell anemia; Spleen; Transcranial doppler

Indexed keywords

HEMOGLOBIN; HYDROXYUREA; PLACEBO;

ACUTE CHEST SYNDROME; ANEMIA; ARTICLE; CHILD; CLINICAL RESEARCH; CONTROLLED STUDY; DISEASE SEVERITY; FEVER; GLOMERULUS FILTRATION RATE; GROUPS BY AGE; HUMAN; INCIDENCE; INFANT; LABORATORY TEST; MAJOR CLINICAL STUDY; NEUROPSYCHOLOGY; OUTCOME ASSESSMENT; PAIN; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SICKLE CELL ANEMIA; SICKLE CELL BETA THALASSEMIA; SPLEEN FUNCTION;

ACUTE DISEASE; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; DOUBLE-BLIND METHOD; FEVER; HEMOGLOBINS; HUMANS; HYDROXYUREA; INFANT; KIDNEY; PAIN; SPLEEN; THORACIC DISEASES;

EID: 84864942605     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24037     Document Type: Article

References (24)

1. Powars DR, Chan LS, Hiti A, et al. Outcome of sickle cell anemia: A 4-decade observational study of 1056 patients. Medicine (Baltimore) 2005; 84: 363-376.
2. Halasa NB, Shankar SM, Talbot TR, et al. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis 2007; 44: 1428-1433.
3. Telfer P, Coen P, Chakravorty S, et al. Clinical outcomes in children with sickle cell disease living in England: A neonatal cohort in East London. Haematologica 2007; 92: 905-912.
4. Wang WC, Pavlakis SG, Helton KJ, et al. MRI abnormalities of the brain in one-year-old children with sickle cell anemia. Pediatr Blood Cancer 2008; 51: 643-646.
5. Wang WC, Langston JW, Steen RG, et al. Abnormalities of the central nervous system in very young children with sickle cell anemia. J Pediatr 1998; 132: 994-998.
6. Castro O, Brambilla DJ, Thorington B, et al. The acute chest syndrome in sickle cell disease: Incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood 1994; 84: 643-649.
7. Gill FM, Brown A, Gallagher D, et al. Newborn experience in the Cooperative Study of Sickle Cell Disease. Pediatrics 1989; 83: 827-829.
8. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994; 330: 1639-1644.
9. Balkaran B, Char G, Morris JS, et al. Stroke in a cohort of patients with homozygous sickle cell disease. J Pediatr 1992; 120: 360-366.
10. Miller ST, Sleeper LA, Pegelow CH, et al. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med 2000; 342: 83-89.
11. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: Rates and risk factors. Blood 1998; 91: 288-294.
12. Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: Reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev 2007; 21: 37-47.
13. Kato GJ, Hebbel RP, Steinberg MH, et al. Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions. Am J Hematol 2009; 84: 618-625.
14. Taylor JGt, Nolan VG, Mendelsohn L, et al. Chronic hyper-hemolysis in sickle cell anemia: Association of vascular complications and mortality with less frequent vasoocclusive pain. PLoS One 2008; 3: e2095.
15. Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: Results of a 17-year, single-center trial (LaSHS). Blood 2010; 115: 2354-2363.
16. Brawley OW, Cornelius LJ, Edwards LR, et al. NIH consensus development statement on hydroxyurea treatment for sickle cell disease. NIH Consens State Sci Statements 2008; 25: 1-30.
17. Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol 2010; 85: 403-408.
18. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995; 332: 1317-1322.
19. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: A multicentre, randomised, controlled trial (BABY HUG). Lancet 2011; 377: 1663-1672.
20. Thompson BW, Miller ST, Rogers ZR, et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): Challenges of study design. Pediatr Blood Cancer 2010; 54: 250-255.
21. Pearson HA. The kidney, hepatobiliary system, and spleen in sickle cell anemia. Ann N Y Acad Sci 1989; 565: 120-125.
22. Lebensburger JD, Pestina TI, Ware RE, et al. Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model. Haematologica 2010; 95: 1599-1603.
23. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med 1991; 325: 11-16.
24. Quinn CT, Lee NJ, Shull EP, et al. Prediction of adverse outcomes in children with sickle cell anemia: A study of the Dallas Newborn Cohort. Blood 2008; 111: 544-548.